Recent Quotes

My Watchlist

Indicators

Markets:

Overview

News

Currencies

International

Treasuries

Ultragenyx Pharmaceutical Inc. - Common Stock (NQ:RARE)

24.69 UNCHANGED

Streaming Delayed Price Updated: 4:00 PM EST, Feb 4, 2026 Add to My Watchlist

Price and Volume

Detailed Quote

Volume	0
Open	24.69
Bid (Size)	24.56 (300)
Ask (Size)	24.92 (200)
Prev. Close	24.69
Today's Range	24.69 - 24.69
52wk Range	18.41 - 46.50
Shares Outstanding	70,814,462
Dividend Yield	N/A

Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News

Investor Notice: Shareholder Rights Law Firm Robbins LLP Informs Investors of the Ultragenyx Pharmaceutical Inc. Securities Class Action Lawsuit

February 04, 2026

From Robbins LLP

Via Business Wire

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Ultragenyx Pharmaceutical Inc. – RARE

February 03, 2026

From Pomerantz LLP

Via GlobeNewswire

Performance

YTD	+4.6%	+4.6%
1 Month	+6.8%	+6.8%
3 Month	-22.5%	-22.5%
6 Month	-12.0%	-12.0%
1 Year	-44.1%	-44.1%

More News

Ultragenyx Announces Positive Longer-Term Data Demonstrating Treatment with UX111 Gene Therapy Results in Sustained, Significant Reductions in CSF-HS and Continued Meaningful Improvements in Clinical Function Across Multiple Developmental Domains in

February 03, 2026

From Ultragenyx Pharmaceutical Inc.

Via GlobeNewswire

RARE Stock Slips 3% Today — What’s Up With Ultragenyx’s Gene Therapy For Sanfilippo Syndrome? ↗

January 30, 2026

Via Stocktwits

Ultragenyx Resubmits Biologics License Application for UX111 AAV Gene Therapy to Treat Sanfilippo Syndrome Type A (MPS IIIA) to U.S. FDA

January 30, 2026

From Ultragenyx Pharmaceutical Inc.

Via GlobeNewswire

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Ultragenyx Pharmaceutical Inc. - RARE

January 27, 2026

From Pomerantz LLP

Via GlobeNewswire

Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

January 23, 2026

From Ultragenyx Pharmaceutical Inc.

Via GlobeNewswire

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Ultragenyx Pharmaceutical Inc. - RARE

January 20, 2026

From Pomerantz LLP

Via GlobeNewswire

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Ultragenyx Pharmaceutical Inc. - RARE

January 13, 2026

From Pomerantz LLP

Via GlobeNewswire

Ultragenyx Provides Financial and Business Updates at J.P. Morgan Annual Healthcare Conference

January 12, 2026

From Ultragenyx Pharmaceutical Inc.

Via GlobeNewswire

Ultragenyx to Present at the 44th Annual J.P. Morgan Healthcare Conference

January 07, 2026

From Ultragenyx Pharmaceutical Inc.

Via GlobeNewswire

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Ultragenyx Pharmaceutical Inc. - RARE

January 06, 2026

From Pomerantz LLP

Via GlobeNewswire

BioMarin’s $4.8 Billion Amicus Acquisition: A Strategic Pivot to Rare Disease Dominance

January 02, 2026

Via MarketMinute

The Great Rebalancing: Thin Holiday Trading and Institutional Pivots Cap a Volatile 2025

January 01, 2026

Via MarketMinute

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Ultragenyx Pharmaceutical Inc. - RARE

December 30, 2025

From Pomerantz LLP

Via GlobeNewswire

Ultragenyx Completes Rolling Submission of Biologics License Application (BLA) to U.S. FDA for DTX401 AAV Gene Therapy for Glycogen Storage Disease Type Ia (GSDIa)

December 30, 2025

From Ultragenyx Pharmaceutical Inc.

Via GlobeNewswire

Why Ultragenyx Pharmaceutical Stock Is Bouncing Back Today ↗

December 30, 2025

Via The Motley Fool

Ultragenyx Stock Eyes Best Day In 17 Months As Wall Street Shifts Focus To 2026 Pipeline After Bone Disease Trial Miss ↗

December 30, 2025

Via Stocktwits

Why Ultragenyx Pharmaceuticals Stock Is Plummeting Today ↗

December 29, 2025

Via The Motley Fool

Which stocks are experiencing notable movement on Monday? ↗

December 29, 2025

Via Chartmill

Biopharma’s Year-End Rollercoaster: Mereo Plummets 90% as BioMarin Seals $4.8 Billion Amicus Deal

December 29, 2025

Via MarketMinute

Keep an eye on the top gainers and losers in Monday's session. ↗

December 29, 2025

Via Chartmill

Why Did RARE Stock Plunge Over 41% Today? ↗

December 29, 2025

Via Stocktwits

Traders are paying attention to the gapping stocks in Monday's session. ↗

December 29, 2025

Via Chartmill

Ultragenyx Announces Phase 3 Orbit and Cosmic Results for Setrusumab (UX143) in Osteogenesis Imperfecta

December 29, 2025

From Ultragenyx Pharmaceutical Inc.

Via GlobeNewswire

Frequently Asked Questions

Is Ultragenyx Pharmaceutical Inc. - Common Stock publicly traded?

Yes, Ultragenyx Pharmaceutical Inc. - Common Stock is publicly traded.

What exchange does Ultragenyx Pharmaceutical Inc. - Common Stock trade on?

Ultragenyx Pharmaceutical Inc. - Common Stock trades on the Nasdaq Stock Market

What is the ticker symbol for Ultragenyx Pharmaceutical Inc. - Common Stock?

The ticker symbol for Ultragenyx Pharmaceutical Inc. - Common Stock is RARE on the Nasdaq Stock Market

What is the current price of Ultragenyx Pharmaceutical Inc. - Common Stock?

The current price of Ultragenyx Pharmaceutical Inc. - Common Stock is 24.69

When was Ultragenyx Pharmaceutical Inc. - Common Stock last traded?

The last trade of Ultragenyx Pharmaceutical Inc. - Common Stock was at 02/04/26 04:00 PM ET

What is the market capitalization of Ultragenyx Pharmaceutical Inc. - Common Stock?

The market capitalization of Ultragenyx Pharmaceutical Inc. - Common Stock is 1.75B

How many shares of Ultragenyx Pharmaceutical Inc. - Common Stock are outstanding?

Ultragenyx Pharmaceutical Inc. - Common Stock has 2B shares outstanding.

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.